And there's so much data now, of course, already a completed trial with reduction of heart attacks and strokes
This implies that, similar to other cardiovascular and metabolic treatments, people cannot discontinue the medication if they wish to maintain their weight loss
A recent study [13] suggested that GLP-1RAs, compared to bupropion-naltrexone, were associated with a higher risk of bowel obstruction in participants with obesity
165,166 Retatrutide has now entered Phase III clinical trials
95% CI: 0.100.50) and 1324 months after treatment initiation compared with pretreatment
At the same time, the pleiotropic, neurotrophic and neuroprotective properties of GLP-1RAs are also obvious and, taking into account the ability to enhance the energy metabolism of neurons and optimize synaptic plasticity these beneficial effects position GLP-1RAs as potential agents modifying brain diseases [109, 110]